ArticleTobacco control2021
Successful countering of tobacco industry efforts to overturn Thailand's ENDS ban.
Article in Tobacco control, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Independent companies in the tobacco supply chain: transparency and environmental social governance.Tobacco control · 2026Article
- Reassessing Spinola et al.: data, sources, and the case for Brazil's e-cigarette ban.Lancet regional health. Americas · 2026Article
- Knowledge and attitudes toward e-cigarette smoking among health and non-health science students: A cross-sectional study.Tobacco prevention & cessation · 2026Article
- Patterns of e-cigarette use by sex and age in Thailand: The National Health Examination Survey 2024-2025.Tobacco induced diseases · 2026Article
- E-cigarette use and associated factors among adolescents and young adults in northern Thailand: evidence from a population-based household survey.Frontiers in public health · 2026Article
- Emerging trends and determinants of electronic cigarette use among young Thai men, 2022-2024.BMC public health · 2025Article
- Article
- Decision to use e-cigarettes and associated factors among students of a university in Northern Thailand.Tobacco induced diseases · 2025Article
- Scoping of Policy Impacts for Regulating E-cigarettes (SPIRE): findings from a data and decision analytic model mapping project.NIHR open research · 2025Article
- Intimidation against advocates and researchers in the tobacco, alcohol and ultra-processed food spaces: a review.Health promotion international · 2024Review
- A thematic analysis of tobacco industry responses to the Scottish Government's consultation on e-cigarette regulation.Health promotion international · 2024Article
- Attitudes towards FCTC Article 5.3 among tobacco control stakeholders in Thailand and their relationship with awareness of tobacco industry tactics.BMJ global health · 2024Article
- The Thai Health Promotion Foundation: Two Decades of Joint Contributions to Addressing Noncommunicable Diseases and Creating Healthy Populations.Global health, science and practice · 2024Article
- Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.Tobacco control · 2024Article
- Prevalence and Covariates of Electronic Cigarette Use among Students Aged 13-15 Years in the Philippines: 2019 Global Youth Tobacco Survey.International journal of environmental research and public health · 2023Article
- Association between socioecological factors and electronic cigarette use among Thai youth: an institution-based cross-sectional study.BMJ open · 2023Article
- Advocacy counterstrategies to tobacco industry interference in policymaking: a scoping review of peer-reviewed literature.Globalization and health · 2023Article
- E-Cigarette Marketing on Social Media: A Scoping Review.Current addiction reports · 2023Article
- Global survey of consumer organizations advocating for safer nicotine products.Public health challenges · 2023Article
- FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.Tobacco control · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAfter Thailand enacted laws to ban the import and sale of all types of electronic nicotine delivery systems (ENDS, including e-cigarettes and heated tobacco products (HTPs)) in 2015, pro-ENDS advocacy groups pressured the government to lift the ban, particularly after Philip Morris International (PMI) started promoting its HTP IQOS in 2017.
methodsWe reviewed information related to ENDS in Thailand between 2014 and 2019 from Thai newspaper articles, meeting minutes and letters submitted to government agencies, websites and social media platforms of pro-ENDS networks and Thai tobacco control organisations.
resultsThe tobacco industry and the pro-ENDS groups used five tactics to try to reverse the Thai ban on ENDS: creating front groups, lobbying decision-makers, running public relations campaigns, seeking to discredit tobacco control advocates and funding pro-tobacco harm reduction research. ENDS Cigarette Smoking Thailand (ECST), a pro-ENDS group in Thailand, worked in parallel to Philip Morris Thailand Limited (PMTL) to oppose the ban. The group connected with international coalitions that promote harm reduction through the PMI-funded Foundation for a Smoke-Free World.
conclusionAlthough ECST and PMTL continuously worked to revoke the ban since 2017, the government still kept ENDS illegal as of October 2020. This decision resulted from the strong commitment and collaboration among Thai tobacco control organisations and their shared vision to protect the public's health from harmful tobacco products. The similar strategies used by the pro-ENDS movement in Thailand and the tobacco companies could inform health advocates and policy-makers in other low and middle income countries facing pressure to market ENDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.